High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
This grant supports innovative research at the HIV and substance use intersection, focusing on new avenues for prevention, treatment, and cure among people who use drugs.
Funder: National Institutes of Health
Due Dates: January 12, 2025 (LOI) | February 11, 2025 (Full) | July 14, 2025 (LOI) | August 13, 2025 (Full) | January 12, 2026 (LOI) | February 11, 2026 (Full) | May 6, 2026 (LOI) | June 5, 2026 (Full) | February 3, 2027 (LOI) | March 5, 2027 (Full) | March 6, 2027 (Final closing)
Funding Amounts: $3M/year total; 3–5 awards/year; project budgets not limited but must reflect actual needs; max project period 5 years.
Summary: Supports innovative research on HIV/AIDS and substance use, aiming to advance prevention, treatment, or cure among people who use drugs.
Key Information: Letter of Intent due 30 days before each application deadline; both clinical trial and non-trial projects accepted.
Description
This NIH opportunity funds high-priority research at the intersection of HIV and substance use, with the goal of advancing scientific knowledge and developing new strategies for HIV prevention, treatment, and cure among people who use drugs (PWUD). The program welcomes innovative research projects—ranging from basic science to clinical and implementation studies—that have the potential to open novel avenues in HIV/AIDS research, especially as they relate to substance use or substance use disorders (SUDs).
Projects must present a detailed research plan, include preliminary data, and clearly describe their relevance to both HIV and substance use. All studies must align with NIH HIV/AIDS Research Priorities (NOT-OD-20-018). Both individual researchers and research teams are eligible to apply.
